Catalyst overview
Research summary
This catalyst tracks a Phase 3 update for Fenebrutinib in Multiple sclerosis, Autoimmune disease. The expected timing is based on the latest available company guidance and may change.
03/02/26:- FENhance 1 met endpoint; submissions planned; full data at AAN 2026. 04/21/26:- FENhance 1/2 Ph3 met endpoints; regulatory submissions planned for RMS and PPMS. 05/06/26:- FENhance 1/2 and FENtrepid Ph3 confirmed fenebrutinib reduced relapses up to ~59% and slowed disability progression. 07/23/26:- FENhance 1/2 Phase 3 relapse and brain-lesion benefit was reiterated; regulatory timing was not provided.
Verification
Confirm timing and program details against the company announcement or filing.